Core Insights - Sichuan Province has announced 25 key industrial sectors to focus on, aiming to seize opportunities from the new technological revolution and industrial transformation [1] Group 1: Key Industrial Sectors - Artificial Intelligence: Focus areas include large models, AI algorithms and software, AI hardware, AI products, and data labeling, primarily in Chengdu, Mianyang, and Zigong [2][3][4][6] - Green Hydrogen: Key components include hydrogen equipment, critical materials, fuel cell systems, and hydrogen-powered vehicles, with major activities centered in Chengdu and Deyang [7][8][9][10][11][12] - Biotechnology: Emphasis on intravenous solutions, blood products, vaccines, and biopharmaceuticals, mainly in Chengdu and Luzhou [13][14] Group 2: Advanced Technologies - Commercial Aerospace: Focus on satellite manufacturing, launch services, and rocket development, primarily in Chengdu and Mianyang [15][16] - Smart Connected Vehicles: Key areas include vehicle networking and autonomous driving technologies, mainly in Chengdu and Yibin [19][20][21] - Low-altitude Economy and Drones: Development of fixed-wing and vertical take-off drones, primarily in Chengdu and Zigong [24] Group 3: Emerging Energy Solutions - Next-Generation Energy Storage: Focus on vanadium and sodium batteries, with significant activities in Leshan and Dazhou [41][42] - Solid-State Batteries: Development of various types of solid-state batteries, primarily in Yibin and Suining [44] - High-Efficiency Solar Cells: Focus on advanced solar cell technologies, particularly in Yibin and Meishan [45][46] Group 4: Advanced Manufacturing - Robotics: Development of service, industrial, and bionic robots, primarily in Chengdu and Mianyang [34] - New Industrial Mother Machines: Focus on high-end CNC machine tools and additive manufacturing, mainly in Deyang and Luzhou [35][36] - Laser Equipment: Development of laser technologies and materials, primarily in Mianyang [38] Group 5: Health and Safety Technologies - Nuclear Medicine: Focus on the manufacturing of nuclear medical equipment and radioactive drug development, primarily in Chengdu and Mianyang [51][52]

Core Viewpoint - The "14th Five-Year Plan" period is a crucial time for Shanxi to achieve high-quality development and deepen comprehensive transformation, laying a solid foundation for the realization of socialist modernization [1] Group 1: Development Opportunities - The overall judgment for Shanxi's development during the "14th Five-Year Plan" period is that opportunities outweigh challenges, with favorable conditions stronger than unfavorable factors [2] - Xi Jinping's personal attention and guidance for Shanxi's development provide significant confidence and support for the province [2] - The upcoming national policies and strategic measures during the "14th Five-Year Plan" period, such as constructing a new energy system and modern industrial system, offer broad space and rare opportunities for Shanxi's development [2] Group 2: Development Advantages - Shanxi is an important birthplace of Chinese civilization and a key energy base, with rich resources in coal and other minerals, as well as a strong foundation in traditional industries like electricity, steel, and chemicals [2] - The province has a unique geographical position and is well-connected, which enhances its importance in the national development landscape [2] - Achievements during the "13th Five-Year Plan" period have laid a solid foundation for high-quality development and modernization in the "14th Five-Year Plan" period [2] Group 3: Challenges and Issues - Shanxi faces prominent issues of unbalanced and insufficient development, with structural, institutional, and quality-related contradictions in its resource-based economy [2] - The transition from old to new growth drivers is still in progress, and there are significant shortcomings in ecological protection and public welfare [2] - The peak in coal consumption expected in the next five years poses urgent demands for industrial transformation and upgrading [2] Group 4: Development Principles - The overall requirements for economic and social development during the "14th Five-Year Plan" period include adherence to Marxism, comprehensive implementation of Xi Jinping's thoughts, and alignment with national strategic deployments [3] - Key principles include maintaining the Party's leadership, prioritizing high-quality development, and ensuring effective market and government collaboration [3] - The focus is on promoting economic growth, enhancing people's well-being, and ensuring decisive progress towards socialist modernization [3]

Core Viewpoint - Zeling Bio has submitted its IPO application to the Hong Kong Stock Exchange, marking its official attempt to go public [1] Group 1: Company Overview - Zeling Bio, founded in 2019, is an innovative biotechnology company focused on late-stage clinical development [4] - The company was incubated under the incentive policies for technology transfer from Sichuan University West China Hospital [2] - The founder, Dr. Chen Lijuan, has extensive experience in the biotechnology industry and holds multiple degrees in chemistry and pharmacy [4][6] Group 2: Financial Information - Zeling Bio recently completed a C-round financing of nearly 600 million RMB, led by Daming Capital and Qiming Venture Partners, bringing its valuation to approximately 3.411 billion RMB [2][8] - The company has raised a total of about 1.18 billion RMB across five financing rounds since its inception [8] - Financial data shows that Zeling Bio reported a net loss of 91.656 million RMB for the fiscal year 2024, with losses expanding to 119.043 million RMB in the first three quarters of 2025 [12][13] Group 3: Product Pipeline - The company has a pipeline of eight products, including two core products in Phase III clinical trials and two candidates in clinical stages [11] - The lead product, Fluorotinib, is aimed at treating myeloproliferative neoplasms, with plans to submit a new drug application to the National Medical Products Administration in 2027 [11][10] - Zeling Bio has not yet commercialized any products and has not generated revenue from product sales [12]

Core Viewpoint - The China Securities Regulatory Commission (CSRC) has requested additional compliance information from Chengyi Biotechnology regarding its overseas listing application, focusing on three main areas: equity structure, capital situation, and domestic operating entities [1][2][3] Group 1: Compliance Requirements - The CSRC requires Chengyi Biotechnology to clarify the compliance of its equity structure and reverse mergers, including whether shareholders holding over 5% have completed foreign exchange registration and if domestic institutional shareholders have followed necessary regulatory procedures [2] - The company must explain the pricing basis and tax payments related to acquisitions of domestic entities, ensuring compliance with regulations on foreign investment in domestic enterprises [2] - The CSRC also demands a conclusion on whether the equity structure and reverse merger processes adhered to existing foreign exchange management, foreign investment, and tax regulations [2] Group 2: Capital Situation - The CSRC has asked for clarification on the shareholding proportions of key stakeholders and whether they should be consolidated, as well as the specific arrangements regarding special shareholder rights and their impact on control [3] - The company is required to disclose whether there have been any shareholding proxies in its historical evolution and if the pricing for new shareholders in the last 12 months was fair and reasonable [3] - The CSRC seeks a conclusive opinion on whether the equity incentives involving domestic individuals complied with foreign exchange registration requirements [3] Group 3: Domestic Operating Entities - Chengyi Biotechnology must provide details on its wholly-owned subsidiary, Shanghai Chengyi, which holds a patent for an extracellular gene expression intervention method, and whether its business aligns with the negative list of foreign investment access [3] - The company is required to disclose any significant litigation, arbitration, or administrative penalties affecting its domestic operations [3] - A conclusive opinion on the legality and compliance of the establishment and historical equity changes of domestic operating entities is also required [3] Group 4: Financial Performance - Chengyi Biotechnology reported revenues of $36.06 million, $221 million, and $557,000 for the years 2023, 2024, and the first half of 2025, respectively, with net profits of -$52.23 million, $139 million, and -$20.11 million during the same periods [4] - The company has only one customer, AstraZeneca, which is also a shareholder, generating revenues of $36 million, $221 million, and $55,680 from this customer in the respective years [4] Group 5: Competitive Landscape - Chengyi Biotechnology believes its pipeline strength and proprietary TRANDD platform provide a significant competitive advantage, but it faces potential competition from multinational pharmaceutical companies and other biotech firms [5] - The company heavily relies on the success of its candidate drugs, and any failure to complete development, obtain regulatory approval, or commercialize these drugs could significantly harm its business and financial outlook [5]

Group 1: Company Overview - Chengdu Zeling Biopharmaceutical Technology Co., Ltd. (Zeling Bio) has submitted its prospectus for an IPO on the Hong Kong Stock Exchange, with Jefferies and CICC as joint sponsors [1] - The company recently completed a C round financing of nearly 600 million RMB, led by Daming Capital and Qiming Venture Partners, bringing its valuation to approximately 3.411 billion RMB [1] - Zeling Bio was founded in 2019 and focuses on innovative therapies for blood diseases, tumors, central nervous system disorders, and immune/inflammatory diseases [2] Group 2: Product Pipeline - Zeling Bio has established three technology platforms: ZeniFol for small molecule drug identification and optimization, ZeniMin for AI-driven drug development, and ZeniScreen for clinical-related screening and target discovery [2] - The company has a pipeline of eight products, including two core products in Phase III clinical trials, two candidates in clinical stages, and four in preclinical stages [3] Group 3: Key Products - The lead product, Malate Fluorotinib (FM), is a first-in-class triple-target inhibitor aimed at treating myeloproliferative neoplasms, including myelofibrosis and polycythemia vera [4] - FM is positioned against Novartis' Ruxolitinib, which has been a cornerstone therapy since its approval in the U.S. in 2011 [4] - Zeling Bio plans to submit a new drug application for FM to the National Medical Products Administration (NMPA) in 2027 and has initiated a Phase IIb head-to-head clinical trial against Ruxolitinib [6] Group 4: Financial Performance - Zeling Bio reported revenues of 19.66 million RMB and 7.12 million RMB for 2024 and the first three quarters of 2025, respectively, with significant losses of 91.66 million RMB and 119.04 million RMB during the same periods [9] - The primary reasons for the losses are high R&D expenditures and changes in the value of redeemable debt, with a significant focus on the two core products FM and PM [10] Group 5: Funding and Shareholding - The company has completed five rounds of financing, raising a total of 1.18 billion RMB, with investors including Qiming Venture Partners and Tencent [12] - Chen Lijuan holds a combined direct and indirect stake of 25.6%, making her the largest shareholder group [14]

Core Viewpoint - 英矽智能 has entered into an exclusive licensing and co-development agreement with Shenzhen Hengtai Biotechnology Co., Ltd. for the ISM8969 project, aimed at accelerating the global development of a new oral NLRP3 inhibitor for central nervous system diseases [1] Group 1: Agreement Details - The agreement grants Shenzhen Hengtai the rights to research, develop, register, produce, and commercialize ISM8969 globally, with both parties holding 50% global rights to the project [1] - 英矽智能 is entitled to receive up to $66 million (approximately HKD 514.8 million) in upfront and milestone payments, including an expected upfront payment of $10 million (approximately HKD 78 million) within 30 days of the agreement's effective date [1] Group 2: Company Background - Shenzhen Hengtai Biotechnology Co., Ltd. was incubated by Shenzhen Pengfu Biomedical Industry Private Equity Investment Fund Partnership and Fosun Pharma, focusing on innovative biotechnology in the field of autoimmune diseases [1] - Established in August 2025, the company aims to introduce and develop innovative pipelines with "best-in-class" potential globally, providing breakthrough treatment solutions through efficient R&D and commercialization capabilities [1]

Core Viewpoint - The announcement details the upcoming listing and circulation of restricted shares for Beijing Innotech Biotechnology Co., Ltd., with a total of 67,647,516 shares set to be released on January 28, 2026, representing 49.3834% of the company's total share capital [1][13]. Group 1: Listing Details - The type of shares being listed is the first issuance of restricted shares, with a total of 67,647,516 shares available for circulation [1]. - The shares were initially issued on July 28, 2022, with a total share capital of 136,060,816 shares, of which 107,471,765 shares are restricted [1][3]. - The restricted shares will be released after a lock-up period of 42 months, extended from the original 36 months due to shareholder commitments [3]. Group 2: Shareholder Commitments - Major shareholders, including the actual controllers, have committed to not transferring their shares for 36 months post-listing, with additional conditions for any subsequent sales [5][10]. - The commitments include a stipulation that any share sales within two years after the lock-up period must not be below the initial offering price [10][11]. - The company has confirmed that all shareholders have adhered to their commitments, ensuring compliance with relevant regulations [12][13]. Group 3: Capital Structure Changes - The company's total share capital has changed from 136,060,816 shares to 136,458,196 shares due to the completion of the first vesting period of the 2023 restricted stock incentive plan [4]. - Further changes in share capital are expected as additional vesting periods are completed in the future [4]. Group 4: Regulatory Compliance - The underwriting institution, Huatai United Securities Co., Ltd., has verified that the listing of restricted shares complies with relevant laws and regulations [12][13]. - The announcement confirms that the information disclosed regarding the restricted shares is accurate and complete [13].

Group 1: IPO Activity Overview - Last week, one small IPO and three SPACs completed pricing, with a total of eight IPO companies (including five larger firms) and one SPAC filing for listings [1][2] - Green Circle Decarb Tech (GCDT), a Chinese producer of thermal energy storage materials, raised $10 million at a market cap of $50 million, with its stock price increasing by 14% [1][2] - Infinite Eagle Acquisition (IEAGU) raised $300 million, OneIM Acquisition (OIMAU) raised $250 million, and FG Imperii Acquisition (FGIIU) raised $200 million, all targeting various sectors [1][2] Group 2: Upcoming IPOs - Eight companies filed for IPOs last week, with five planning to raise over $100 million, led by Brazilian digital bank AGI (AGBK) aiming for approximately $1 billion [2][4] - Liftoff Mobile (LFTO) plans to raise about $800 million, while SOLV Energy (MWH) aims for around $750 million [2][4] Group 3: Future IPOs and Market Outlook - EquipmentShare.com (EQPT) plans to raise $747 million, with a post-IPO market cap exceeding $6.7 billion, focusing on equipment rental services [5] - BitGo Holdings (BTGO) aims for a $2 billion valuation while raising $189 million, providing a digital asset custody and trading platform [6][7]

Group 1 - The China Securities Regulatory Commission (CSRC) has issued supplementary material requirements for six companies, including Chengyi Biotechnology, regarding compliance with capital structure and reverse mergers [1] - Chengyi Biotechnology has submitted a listing application to the Hong Kong Stock Exchange, with Jefferies, BofA Securities, and CICC as joint sponsors [1] - The CSRC requires Chengyi Biotechnology to clarify various aspects of its capital structure and compliance with foreign exchange management regulations, including shareholder registration and pricing of acquisitions [1][2] Group 2 - Chengyi Biotechnology is a clinical-stage global biotechnology company focused on developing next-generation oral small molecule drugs to address unmet medical needs in cardiovascular metabolic diseases and inflammatory diseases [3] - The company utilizes its proprietary TRANDD platform to create a product pipeline aimed at effective outcomes in weight management, metabolic-associated fatty liver disease, osteoarthritis pain, and other cardiovascular metabolic diseases [3]

Core Viewpoint - The announcement highlights a collaboration between HBM Alpha Therapeutics and Spruce Biosciences to develop novel CRH-targeted therapies for various diseases, indicating a strategic move in the biopharmaceutical sector [1] Group 1: Partnership Details - HBM Alpha Therapeutics has entered into a licensing and collaboration agreement with Spruce Biosciences Inc. to advance new CRH-targeted therapies [1] - Under the agreement, HBMAT and its affiliates will receive warrants related to minority equity to purchase common stock of Spruce [1] Group 2: Equity Stake - As of January 19, 2026, the company and HBMAT will exercise the warrants, resulting in the company holding approximately 3.8% of Spruce's outstanding shares and about 3.1% of Spruce's fully diluted shares [1]